ALPN vs. PRGO, ALKS, NUVL, INSM, MDGL, CRNX, SMMT, BHVN, AXSM, and RARE
Should you be buying Alpine Immune Sciences stock or one of its competitors? The main competitors of Alpine Immune Sciences include Perrigo (PRGO), Alkermes (ALKS), Nuvalent (NUVL), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Crinetics Pharmaceuticals (CRNX), Summit Therapeutics (SMMT), Biohaven (BHVN), Axsome Therapeutics (AXSM), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical preparations" industry.
Alpine Immune Sciences (NASDAQ:ALPN) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
75.2% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 42.3% of Alpine Immune Sciences shares are owned by insiders. Comparatively, 0.7% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Alpine Immune Sciences had 5 more articles in the media than Perrigo. MarketBeat recorded 15 mentions for Alpine Immune Sciences and 10 mentions for Perrigo. Alpine Immune Sciences' average media sentiment score of 1.40 beat Perrigo's score of 0.49 indicating that Alpine Immune Sciences is being referred to more favorably in the media.
Alpine Immune Sciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Alpine Immune Sciences presently has a consensus target price of $52.33, indicating a potential downside of 19.45%. Perrigo has a consensus target price of $40.67, indicating a potential upside of 35.02%. Given Perrigo's stronger consensus rating and higher probable upside, analysts clearly believe Perrigo is more favorable than Alpine Immune Sciences.
Perrigo received 384 more outperform votes than Alpine Immune Sciences when rated by MarketBeat users. Likewise, 66.75% of users gave Perrigo an outperform vote while only 64.46% of users gave Alpine Immune Sciences an outperform vote.
Perrigo has a net margin of -0.17% compared to Alpine Immune Sciences' net margin of -65.17%. Perrigo's return on equity of 6.96% beat Alpine Immune Sciences' return on equity.
Perrigo has higher revenue and earnings than Alpine Immune Sciences. Perrigo is trading at a lower price-to-earnings ratio than Alpine Immune Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Perrigo beats Alpine Immune Sciences on 11 of the 17 factors compared between the two stocks.
Get Alpine Immune Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpine Immune Sciences Competitors List
Related Companies and Tools
